NCT06961214View on ClinicalTrials.gov

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

PHASE3RecruitingINTERVENTIONAL
Enrollment

960

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

August 21, 2029

Study Completion Date

August 21, 2029

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Depemokimab

Depemokimab as a sterile liquid formulation will be administered.

DRUG

Placebo

Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered

Trial Locations (1)

32825

RECRUITING

GSK Investigational Site, Orlando

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06961214 - Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | Biotech Hunter | Biotech Hunter